{ "entity_id": "B-002589", "folder": "Pharmaceutical-Benefits-Advisory-Committee", "name": "Pharmaceutical Benefits Advisory Committee", "type": "Statutory Body", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "http://www.pbs.gov.au/info/industry/listing/participants/pbac", "data_status": "partial", "completeness": { "has_strategy_brief": false, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": false, "has_kpi_results": false, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_global_initiatives_structured": false, "n_global_initiatives": 0, "has_ideas": true, "has_artifacts": true, "n_ideas": 12, "n_legislation": 0, "n_artifacts": 4, "n_kpi_targets": 0, "n_kpi_results": 0, "n_outcomes": 0, "verified_own_data": true }, "strategy_profile": { "status": "needs_review", "confidence": "medium", "summary": "", "official_site_url": "http://www.pbs.gov.au/info/industry/listing/participants/pbac", "source_documents": [ { "type": "pb", "title": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)", "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf", "period": "2026", "confidence": "medium" }, { "type": "pb", "title": "December 2025 PBAC Intracycle Meeting (PDF 254KB)", "url": "http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf", "period": "2025", "confidence": "medium" } ], "purpose": null, "vision": null, "strategic_priorities": [], "values": [], "outcomes": [], "performance_measures": [], "document_alignment_terms": { "must_support": [], "watch_terms": [], "avoid_claiming_without_evidence": [] }, "review_note": "Structured strategy exists but is incomplete." }, "global_initiatives": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": null, "purposes_source_page": null, "how_we_deliver": null, "how_we_deliver_source_page": null, "government_priorities": [], "outcomes": [], "values": [], "values_framework_name": null, "kpi_targets_2025_26": [], "kpi_results_2024_25": [], "_source_urls": { "annual_report_url": "", "corporate_plan_url": "" } }, "ideas": [ { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Case Processing", "scale": "small", "title": "Triage queue for stuck or ageing cases", "idea": "Use existing case data to flag ageing, duplicate, incomplete, or high-risk cases for earlier intervention.", "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Case Processing", "scale": "large", "title": "End-to-end case processing redesign", "idea": "Redesign the case pathway around risk-based triage, reusable evidence, and automated eligibility checks.", "quote": "The authority application must be made in writing and must include:\n(a) details of the proposed prescription(s); and\n(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the\nwebsite specified in the Administrative Advice).\nteduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack\n11806J Max.Qty Packs No. of Rpts Premium $ DPMQ $ Brand Name and Manufacturer\n1 5 ..", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Applicants / case officers", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[pages 28,29]\ns)\nAlternatively, applications for authority to prescribe can be submitted online using the form upload facility in Health\nProfessional Online Services (HPOS) at www.servicesaustralia.gov.au/hpos\nOr mailed to:\nServices Australia\nComplex Drugs\nReply Paid 9826\nHOBART TAS 7001\nAuthority required\nSevere aplastic anaemia\nTreatment Phase: Initial treatment - Second line treatment\nClinical criteria:\n• The condition must be severe aplastic anaemia, AND\n• Patient must not have achieved an adequate response to prior immunosuppressive therapy including anti-thymocyte\nantibody and ciclosporin; OR\n• Patient must have relapsed following prior immunosuppressive therapy including anti-thymocyte antibody and ciclosporin,\nAND\n• Patient must not receive more than 16 weeks of treatment under this restriction.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "[pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "[pages 42,43]\nt must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR\n• Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment\nis for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per\ndispensing.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "[pages 56,57]\nment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of\nthis PPI, (iii) the sole form of PPI, AND\n• Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI)\nadministered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom\ncontrol; OR\n• Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily,\nwith the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR\n• Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-\nestablishment of symptom control; OR", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "Authority Required (STREAMLINED)\n18113\nChronic heart failure\nClinical criteria:\n• The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this\npatient, AND\n• Patient must be symptomatic with NYHA classes II, III or IV prior to initiating treatment with this drug, AND\n• Patient must have a documented left ventricular ejection fraction (LVEF) of greater than 40%, AND\n• Patient must have documented evidence of structural changes in the heart on echocardiography that would be expected\nto cause diastolic dysfunction (e.g. left ventricular hypertrophy), AND\n• Patient must have documented evidence of at least one of the following:\n(i) diastolic dysfunction with high filling pressure on echocardiography, stress echocardiography or cardiac\ncatheterisation;", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "Authority Required (STREAMLINED)\n18113\nChronic heart failure\nClinical criteria:\n• The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this\npatient, AND\n• Patient must be symptomatic with NYHA classes II, III or IV prior to initiating treatment with this drug, AND\n• Patient must have a documented left ventricular ejection fraction (LVEF) of greater than 40%, AND\n• Patient must have documented evidence of structural changes in the heart on echocardiography that would be expected\nto cause diastolic dysfunction (e.g. left ventricular hypertrophy), AND\n• Patient must have documented evidence of at least one of the following:\n(i) diastolic dysfunction with high filling pressure on echocardiography, stress echocardiography or cardiac\ncatheterisation;", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "[Page 13]\n13044M Azacitidine Sandoz, SZ – AZACITIDINE, azacitidine 100 mg injection, 1 vial\nHighly Specialised Drugs Program (Community Access)\nDeletions\nDeletion – Brand\n11501H Octreotide Depot, TB – OCTREOTIDE, octreotide 10 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11537F Octreotide Depot, TB – OCTREOTIDE, octreotide 20 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11512X Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11896D Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\nDeletion – Equivalence Indicator", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "[Page 13]\n13044M Azacitidine Sandoz, SZ – AZACITIDINE, azacitidine 100 mg injection, 1 vial\nHighly Specialised Drugs Program (Community Access)\nDeletions\nDeletion – Brand\n11501H Octreotide Depot, TB – OCTREOTIDE, octreotide 10 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11537F Octreotide Depot, TB – OCTREOTIDE, octreotide 20 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11512X Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\n11896D Octreotide Depot, TB – OCTREOTIDE, octreotide 30 mg modified release injection [1 vial] (&) inert substance\ndiluent [2 mL syringe], 1 pack\nDeletion – Equivalence Indicator", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "pbs/2026.pdf (http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] } ], "legislation_administered": [], "artifacts": [ { "category": "pbs", "year": "2026", "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-soc.pdf", "file": "pbs/2026.pdf", "bytes": 371591, "link_text": "Schedule of Pharmaceutical Benefits (Summary of Changes) (PDF 2MB)" }, { "category": "pbs", "year": "2025", "url": "http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/agenda/pdf/2025/PBAC-Intracycle-meeting-agenda-DECEMBER-2025.pdf", "file": "pbs/2025.pdf", "bytes": 275754, "link_text": "December 2025 PBAC Intracycle Meeting (PDF 254KB)" }, { "category": "other-pdfs", "year": "2026", "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf", "file": "other-pdfs/2026-05-01-general-schedule-Volume-1.pdf", "bytes": 14155691, "link_text": "Schedule of Pharmaceutical Benefits (Volume 1 - General Schedule) (PDF 20MB)" }, { "category": "other-pdfs", "year": "2026", "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-2.pdf", "file": "other-pdfs/2026-05-01-general-schedule-Volume-2.pdf", "bytes": 9898431, "link_text": "Schedule of Pharmaceutical Benefits (Volume 2 - Section 100) (PDF 10MB)" } ], "_meta": { "snapshot_built_at": "2026-05-14T02:13:32+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "Pharmaceutical-Benefits-Advisory-Committee", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "other-pdfs\\2026-05-01-general-schedule-Volume-1.txt", "url": "http://www.pbs.gov.au/publication/schedule/2026/05/2026-05-01-general-schedule-Volume-1.pdf", "year": "2026-05-01-general-schedule-Volume-1" }, "usage": { "input_tokens": 18237, "output_tokens": 155, "total_tokens": 18392, "model": "nova-micro" }, "cost_usd": 0.0006599950000000001, "elapsed_seconds": 8.78, "generated_at": "2026-05-13T05:18:18+00:00" }, "ideas_manifest": { "entity_id": "B-002589", "entity_name": "Pharmaceutical Benefits Advisory Committee", "folder_name": "Pharmaceutical-Benefits-Advisory-Committee", "generated_at": "2026-05-09T23:05:37.825944+00:00", "idea_count": 12, "markdown": "ideas/Pharmaceutical-Benefits-Advisory-Committee_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "Pharmaceutical-Benefits-Advisory-Committee_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }